Vertex/CRISPR selects RoslinCT as CDMO for Casgevy
Cell and gene therapy CDMO RoslinCT will commercially produce Vertex and CRISPR Therapeutics’ CRISPR/Cas9 gene-edited therapy exa-cel. Vertex Pharmaceuticals has picked UK-based contract development and manufacturing organization (CDMO) RoslinCT – a spinout from the Roslin Institute – for ...
Japan’s regulators have approved ARCT-154, CSL and Arcturus’ COVID-19 vaccine based on self-amplified messenger RNA (sa-mRNA) technology.
...
At Sartorius, we offer a wide range of high-quality media and critical raw materials. We help you find the best formulation for your processes by ...
Hovione has acquired ExtremoChem, a firm focused on the development and commercialization of synthetic sugars to stabilize the performance of bio ...
Dyadic will use its C1 platform in partnership with Rubic One Health and Afreximaxbank to manufacture vaccines in South Africa.Â
Dyadic Inter ...
Recent Tweets
-
To everyone at #BiotechWeekBoston - thanks for a great event & see you next year!
1 year ago
-
@Dan5tanton hosting BioProcess Insider’s State of the Industry chat at the spotlight theater here at #BWB2022 https://t.co/UBCZCf1Jng
1 year ago
-
@ADaviesDHCG I couldn’t find a seat, it was so busy! A great talk with some really interesting and helpful talks ma… https://t.co/5b3mjes9tb
1 year ago
-
@ADaviesDHCG on stage at the Spotlight Theater discussing CGT capacity & demand #BWB2022 https://t.co/d5T0KYm7mp
1 year ago
